Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02727972 · ClinicalTrials.gov registry record · NA
Examination of Glutamate and mGluR5 in Psychiatric Disorders
A NA study of Major Depressive Disorder and Post Traumatic Stress Disorder, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 180
- Enrollment target
- 1
- Study location
NCT02727972: Completed NA study of Major Depressive Disorder and Post Traumatic Stress Disorder, sponsored by Yale University.
NCT02727972 is a NA study of Major Depressive Disorder and Post Traumatic Stress Disorder that has completed, run by Yale University. The registered enrollment target is 180 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02727972, a NA study of Major Depressive Disorder and Post Traumatic Stress Disorder, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is designed to look at the involvement of the glutamate system in depression. Each subject will undergo a screening appointment to determine study eligibility. Thereafter, the study will take 2 or 3 visits depending on schedule availability and will consist of one MRI scan, and PET scan. Subjects will also participate in cognitive testing. Depending on camera time, staff availability and subject schedule, total study participation may last 1-2 months.
Conditions Studied
Interventions
- OTHER MRI
- BEHAVIORAL Cognitive Testing
- RADIATION PET
Study Locations (1)
Connecticut
- PET Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2012-02-21 |
| Est. Completion | 2022-01-13 |
| Phase | NA |
What the finished NCT02727972 record still lists
NCT02727972 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (52% lower).
The record links to 3 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 3 interventions - of which MRI is the first listed.
NCT02727972 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT02727972 about?
NCT02727972 is a clinical study titled "Examination of Glutamate and mGluR5 in Psychiatric Disorders". This research study is designed to look at the involvement of the glutamate system in depression. Each subject will undergo a screening appointment to determine study eligibility. Thereafter, the study will take 2 or 3 visits depending on schedule availability and will consist of one MRI scan, and P...
What is the current status of trial NCT02727972?
This trial is currently completed. It is a NA study. The enrollment target is 180 participants. The study started on 2012-02-21. Estimated completion is 2022-01-13.
What conditions does trial NCT02727972 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Post Traumatic Stress Disorder, Bipolar Disorder.
What interventions are being tested in trial NCT02727972?
The interventions under investigation include: MRI (OTHER), Cognitive Testing (BEHAVIORAL), PET (RADIATION).
Who is sponsoring clinical trial NCT02727972?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02727972 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02727972's enrollment target sits among peer trials
180 83rd of 282 higher than 198 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Targeting Large-scale Networks in Depression With Real-time Functional Magnetic Resonance Imaging (fMRI) Neurofeedback
RECRUITING · NA
-
Neural Correlates of Stress and Perceived Control in Adolescent Depression
RECRUITING · NA
-
Positive Processes and Transition to Health (PATH)
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Amygdala Neurofeedback for Depression - Large Scale Clinical Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI